TRIAL DATA
AZUR-4 trial testing immunotherapy before surgery in MSS colon cancer — Clinical Colorectal Cancer
AZUR-4 is a phase 2, open-label, randomized study comparing neoadjuvant (before surgery) dostarlimab plus CAPEOX chemotherapy versus CAPEOX alone in previously untreated stage III or high-risk stage II mismatch repair-proficient/microsatellite stable (pMMR/MSS) resectable colon cancer. Most colorectal cancers are MSS and don't typically respond well to immunotherapy alone.